Gilead Sciences
(NQ:
GILD
)
76.77
+0.28 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Market Briefing For Tuesday, May 25
May 25, 2021
Seasonal bias kicked-in, to the upside, ahead of Memorial Day, primarily it seems led by rotational rebounds in the usual suspects of momentum stocks, but also as Oil moved above 65 / bb,; suggesting...
Via
Talk Markets
NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops
May 24, 2021
NGM Biopharmaceuticals joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash.
Via
Investor's Business Daily
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
May 24, 2021
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date...
Via
Benzinga
'Fast Money' Traders Weigh In On IBB And Gilead
May 21, 2021
On CNBC's "Fast Money," Tim Seymour spoke about a possible break out in iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). He said traders should be defensive in a high...
Via
Benzinga
How Small Biotech Allogene Is Making Waves For Gilead, Novartis
May 20, 2021
Allogene Therapeutics said its donor cell-derived cancer treatment was successful for six months, and ALLO stock popped Thursday.
Via
Investor's Business Daily
This Top Healthcare Dividend Stock Is a Bargain Right Now
May 20, 2021
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world.
Via
The Motley Fool
Exposures
COVID-19
2 High-Yield Dividend Stocks to Buy Now
May 20, 2021
They pay more than double what you'd earn with the average stock in the S&P 500.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
This High-Quality, Cheap Stock Is Rated A “Buy” And Looks 10% Undervalued
May 18, 2021
Morningstar rates GILD as a 4-star stock, with a fair value estimate of $81.00. CFRA rates GILD as a 3-star “HOLD”, with a 12-month target price of $66.00.
Via
Talk Markets
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
May 11, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...
Via
Benzinga
Why Humanigen Stock Vaulted Higher Today
May 05, 2021
Detailed results from a late-stage study of the company's lead candidate were published online.
Via
The Motley Fool
Exposures
COVID-19
Dogecoin Fulfills 'Doge Day' Goal Of 69 Cents Weeks Later, Surpasses Snapchat, GM In Valuation
May 05, 2021
The joke cryptocurrency Dogecoin (DOGE) touched a fresh all-time high in the early hours of Wednesday, crossing the much sought-af...
Via
Benzinga
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
May 04, 2021
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
Via
The Motley Fool
2 Must-Own Biotech Stocks To Buy In May
May 03, 2021
After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks such as Gilead Sciences...
Via
Talk Markets
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
May 03, 2021
Here's the list of some unusual options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest...
Via
Benzinga
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
May 01, 2021
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap...
Via
Talk Markets
Exposures
COVID-19
Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings
April 30, 2021
Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but...
Via
Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug
April 30, 2021
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.
Via
The Motley Fool
Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript
April 30, 2021
GILD earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
15 Stocks Moving In Thursday's After-Hours Session
April 29, 2021
Gainers Amazon (NASDAQ: AMZN) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 sales guidance above...
Via
Benzinga
Recap: Gilead Sciences Q1 Earnings
April 29, 2021
Shares of Gilead Sciences (NASDAQ:GILD) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 23.81% year over...
Via
Benzinga
Gilead Stock Dives On Wide First-Quarter Sales Miss, Earnings Meet
April 29, 2021
Late Thursday, Gilead reported adjusted income of $2.08 a share on $6.42 billion in sales for its first quarter. In response, Gilead stock fell.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Healthcare ETFs on Radar As Q1 Earnings Unfold
April 28, 2021
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production
April 27, 2021
Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
The Smartest Stocks to Buy With $1,000 Right Now
April 26, 2021
These fundamentally strong stocks can yield solid returns in the coming years.
Via
The Motley Fool
Topics
Electric Vehicles
Exposures
Electric Vehicles
Should You Buy Gilead Sciences in April?
April 21, 2021
Gilead Sciences had a stellar 2020, but this year is looking a little more perilous.
Via
The Motley Fool
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
April 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.